Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.

CONCLUSION: Our data documented drug efficacy that is satisfactory for this high-risk subset of patients with an acceptable toxicity profile. Results indicate that pixantrone could be a significant treatment option in patients with R/R aggressive DLBCL treated in everyday clinical practice. PMID: 33040061 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33040061?dopt=Abstract

Source: Acta Haematologica - October 9, 2020 Category: Hematology Authors: Zinzani PL, Bregni M, Spione M, Mitterer M, Musuraca G, Bugli A, Piazza F, Pinto A Tags: Acta Haematol Source Type: research